StemCell Therapy

Fort Collins, Colorado Reports Globe recently added the Genetic Engineering Market research report which has an in-depth scenario analysis of the market size, share, demand, growth, trends, and the forecast from 2020-2027. The report deals with the impact analysis of the COVID-19 pandemic. The COVID-19 pandemic has affected export-import, demand and industry trends and is expected to have economic effects on the market. The report provides a comprehensive analysis of the impact of the pandemic across the industry and an overview of a post-COVID-19 market scenario.

The report mainly mentions definitions, classifications, applications, and market reviews of the Genetic Engineering industry. It also includes product portfolios, manufacturing processes, cost analyzes, structures and the gross margin of the industry. It also offers a comprehensive analysis of key competitors, their regional breakdown and market size.

Global Genetic Engineering Market to reach USD XX billion by 2025.Global Genetic Engineering Market valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2019-2026.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

The report provides a comprehensive analysis in an organized manner in the form of tables, graphs, charts, figures, and diagrams. The organized data paves the way for thorough examination and research of the current and future outlook of the market.

The examination of the Genetic Engineering industry provides an in-depth analysis of the key market drivers, opportunities, challenges, and their impact on the working of the market. The technological advancements and product developments, driving the demands of the market are also covered in the report.

The report provides comprehensive data on the Genetic Engineering market and its trends to assist the reader in formulating decisions to accelerate the business. The report provides a complete overview of the economic scenario of the market, along with benefits and limitations.

Genetic Engineering market report contains industrial chain analysis and value chain analysis to provide a comprehensive view of the Genetic Engineering market. The study is composed of market analysis along with a detailed analysis of the application segments, product types, market size, growth rate, and current and emerging trends in the industry.

The report further studies the segmentation of the market based on product types offered in the market and their end-use/applications.

By Devices:

By Techniques:

By End-User:

By Application:

Geographically, the market is spread across several key geographical regions, and the report covers the regional analysis as well as the production, consumption, revenue, and market share in those regions for the forecast period of 2020-2027. The regions includeNorth America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa.

Radical Coverage of the Genetic Engineering Market:

Thank you for reading our report. For further queries on the report and customization, please connect with us. Our team will ensure you get the report best suited for your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View original post here:
Genetic Engineering Market 2020 Share Growing Rapidly with Recent Trends, Revenue, Top Players and Forecast to 2027 - Scientect

Insecticidal Bt (Bacillus thuringiensis) cotton is the first and only GM (genetically modified) crop that has been approved in India. It has been cultivated in the country for more than 20 years. In a formal statement to the Supreme Court of India, the Indian government has asserted that hybrid Bt cotton is an outstanding success. It therefore argues that Bt cotton is a templatefor the introduction of GM food crops.

However, over the last week, two important webinars took place that challenged the governments stance. The first was on Bt cotton and involved a panel of internationally renowned scientists who conclusively debunked the myth of Bt cotton success in India. The webinar, organised by the Centre for Sustainable Agriculture and Jatan, focused on an evidence-based evaluation of 18 years of approved Bt cotton cultivation in India.

The second webinar discussed the case of Bt brinjal, which the countrys apex regulatory body, the Genetic Engineering Appraisal Committee (GEAC), has brought to the brink of commercialisation. The webinar highlighted deep-seated problems with regulatory processes in India and outlined how the GEAC is dogged by secrecy, conflicts of interest and (scientific) fraud: participants outlined how the GEAC has been colluding with crop developers and seed companies to drive GM crops into agriculture.

Bt cotton failure

The panel for the Bt cotton webinar (YouTube: Bt Cotton in India: Myths & Realities An Evidence-Based Evaluation) on 24 August included Dr Andrew Paul Gutierrez, senior emeritus professor in the College of Natural Resources at the University of California at Berkeley; Dr Keshav Kranthi, former director of Central Institute for Cotton Research in India; Dr Peter Kenmore, former FAO representative in India, and Dr Hans Herren, World Food Prize Laureate.

Dr Herren said that the failure of Bt cotton is a classic representation of what an unsound science of plant protection and faulty direction of agricultural development can lead to.

He explained:

Bt hybrid technology in India represents an error-driven policy that has led to the denial and non-implementation of the real solutions for the revival of cotton in India, which lie in HDSS (high density short season) planting of non-Bt/GMO cotton in pure line varieties of native desi species and American cotton species.

He argued that a transformation of agriculture and the food system is required; one that entails a shift to agroecology, which includes regenerative, organic, biodynamic, permaculture and natural farming practices.

Dr Kenmore said that Bt cotton is an aging pest control technology:

It follows the same path worn down by generations of insecticide molecules from arsenic to DDT to BHC to endosulfan to monocrotophos to carbaryl to imidacloprid. In-house research aims for each molecule to be packaged biochemically, legally and commercially before it is released and promoted. Corporate and public policy actors then claim yield increases but deliver no more than temporary pest suppression, secondary pest release and pest resistance.

Recurrent cycles of crises have sparked public action and ecological field research which creates locally adapted agroecological strategies.

He added that this agroecology:

now gathers global support from citizens groups, governments and UN-FAO. Their robust local solutions in Indian cotton do not require any new molecules, including endo-toxins like in Bt cotton.

Prof Gutierrez presented the ecological reasons as to why hybrid Bt cotton failed in India: long season Bt cotton introduced in India was incorporated into hybrids that trapped farmers into biotech and insecticide treadmills that benefited GMO seed manufacturers.

He noted:

The cultivation of long-season hybrid Bt cotton in rainfed areas is unique to India. It is a value capture mechanism that does not contribute to yield, is a major contributor to low yield stagnation and contributes to increasing production costs.

Prof Gutierrez asserted that increases in cotton farmer suicides are related to the resulting economic distress.

He argued:

A viable solution to the current GM hybrid system is adoption of improved non-GM high-density short-season fertile cotton varieties.

Presenting data on yields, insecticide usage, irrigation, fertiliser usage and pest incidence and resistance, Dr Keshav Kranthi said that a critical analysis of official statistics (eands.dacnet.nic.inandcotcorp.gov.in) shows that Bt hybrid technology has not been providing any tangible benefits in India either in yield or insecticide usage.

He said that cotton yields are the lowest in the world in Maharashtra, despite being saturated with Bt hybrids and the highest use of fertilisers. Yields in Maharashtra are less than in rainfed Africa where there is hardly any usage of technologies such as Bt, hybrids, fertilisers, pesticides or irrigation.

It is revealing that Indian cotton yields rank 36th in the world and have been stagnant in the past 15 years and insecticide usage has been constantly increasing after 2005, despite an increase in area under Bt cotton.

Dr Kranthi argued that research also shows that the Bt hybrid technology has failed the test of sustainability with resistance in pink bollworm to Bt cotton, increasing sucking pest infestation, increasing trends in insecticide and fertiliser usage, increasing costs and negative net returns in 2014 and 2015.

Dr Herren said that GMOs exemplify the case of a technology searching for an application:

It is essentially about treating symptoms, rather than taking a systems approach to create resilient, productive and bio-diverse food systems in the widest sense and to provide sustainable and affordable solutions in its social, environmental and economic dimensions.

He went on to argue that the failure of Bt cotton is a classic representation of what an unsound science of plant protection and a faulty direction of agricultural development can lead to:

We need to push aside the vested interests blocking the transformation with the baseless arguments of the world needs more food and design and implement policies that are forward looking We have all the needed scientific and practical evidence that the agroecological approaches to food and nutrition security work successfully.

Bt brinjal the danger is back

The governments attempt to use a failed technology as a template for driving GMOs into agriculture has been exposed. Nevertheless, the GEAC has been moving forward with late-stage trials of Bt brinjal, while ignoring the issues and arguments against its commercialisation that were forwarded a decade ago.

In February 2010, the Indian government placed an indefinite moratorium on the release of Bt brinjal after numerous independent scientific experts from India and abroad had pointed out safety concerns based on data and reports in the biosafety dossier that Mahyco, the crop developer, had submitted to the regulators.

The then Minister of the Ministry of Environment and Forests Jairam Ramesh had instituted a unique four-month scientific enquiry and public hearings. His decision to reject the commercialisation of Bt brinjal was supported by advice from the renowned scientists.Their collective appraisals demonstrated serious environmental and biosafety concerns.

Jairam Ramesh pronounced a moratorium on Bt brinjal in February 2010 by stating:

it is my duty to adopt a cautious, precautionary principle-based approach and impose a moratorium on the release of Bt brinjal, till such time independent scientific studies establish, to the satisfaction of both the public and professionals, the safety of the product from the point of view of its long-term impact on human health and environment, including the rich genetic wealth existing in brinjal in our country.

The moratorium has not been lifted and the conditions he set out have still not been met. Moreover, five high-level reportshave advised against the adoption of GM crops in India. Appointed by the Supreme Court, the Technical Expert Committee (TEC) Final Report (2013) was scathing about the prevailing regulatory system and highlighted its inadequacies. The TEC went a step further by recommending a 10-year moratorium on the commercial release of all GM crops.

The regulatory process was shown to lack competency, possessed endemic conflicts of interest and demonstrated a lack of expertise in GMO risk assessment protocols, including food safety assessment and the assessment of environmental impacts.

Ten years on and regulators have done nothing to address this woeful state of affairs. As we have seen with the relentless push to get GM mustard commercialised, the problems persist. Through numerous submissions to the Supreme Court, Aruna Rodrigues has described how GM mustard is being forced through withflawed tests (or no tests) and a lack of public scrutiny.Regulators are seriously conflicted: they promote GMOs openly, fund them and then regulate them.

And this is precisely what the webinar Bt brinjal the danger is back (watch onYouTube) discussed on 27 August. Organised by the Coalition for a GM-Free India, the webinar was arranged because the regulators have again brought to the brink of commercialisation a new Bt brinjal event a different Bt brinjal than the 2010 version. Also included in the webinar were the experiences of Bt brinjal introduction in Bangladesh.

Dr Ramanjaneyulu (Centre for Sustainable Agriculture) highlighted how need has never been established for Bt brinjal of which India is a recognised centre of diversity. The argument for Bt brinjal in the run-up to Jairam Rameshs moratorium was that pesticide use is a problem in containing the brinjal fruit and shoot borer. He noted that Bt brinjal was promoted by Monsanto, USAID and Cornell University, but serious protocol violations, environmental contamination concerns and potential adverse health impacts were discovered.

He outlined simple non-pesticidal, agroecological management practises that can and are being used to deal with the brinjal fruit and shoot borer.

Farida Akhter of UBINIG (Policy Research for Development Alternative) outlined how the introduction of Bt brinjal in Bangladesh was not needed but imposed on the country, which has 248 varieties of brinjal. Where pesticide use is problematic, she argued that it concerns hybrid varieties rather than traditional cultivars of which 24 varieties are resistant to fruit and shoot borer.

Akhter said that poor quality brinjal and financial losses for farmers have been major issues. Many have abandoned Bt brinjal, but farmers have received incentives to cultivate and where they have done so, fertiliser use has increased and there have been many pest attacks, with 35 different types of pesticides applied.

The Bill Gates-funded Cornell Alliance for Science, a public relations entity that promotes GM agriculture, and USAID, which serves the interests of the GMO biotech sector, tried to sell Bt brinjal on the basis it would save people from the overuse of pesticides and related illnesses. But Akhter argued that Bangladesh was targeted because the Philippines and India had rejected Bt brinjal. Again, protocol violations occurred leading to its introduction and Akhter concluded that there was no scientific basis for Bt brinjal: its introduction was political.

As for India, event EE1, the initial Bt brinjal, has now been replaced by event 142, a different Bt brinjal. Kavitha Kuruganti (Alliance for Sustainable and Holistic Agriculture) explained this in the webinar and notes that the GEAC, immediately after the 2010 moratorium was announced, went straight ahead and sanctioned new trials for this Bt brinjal. The GEAC basically stated that the moratorium did not apply to this version, while ignoring all the criticisms about lack of competence, conflicts of interest, non-transparency and protocol violations. It was effectively business as usual!

With event EE1, Kuruganti implied that the GEAC acted more like a servant for Mayco and its Monsanto master. Nothing has changed. She noted the ongoing revolving door between crop developers (even patent holders) and regulators. As before, developers-cum-lobbyists were actually sitting on regulatory bodies as event 142 was proceeding.

Under public-private-partnership arrangements, event 142 has been licensed to private companies for biosafety testing/commercialisation. Despite major concerns, the GEAC has pressed ahead with various trials. In May 2020, under lockdown, Kuruganti notes that the GEAC held a virtual meeting and sanctioned what were effectively final trials prior to commercialisation. She explains that important information and vital data is not in the public domain.

According to Kuruganti, the regulator sits with the crop developer and the companies and grant biosafety clearance, claiming all tests (soil, pollen flow, toxicity, etc) are complete. What is also disturbing is that these licensed companies have closed and opened under new names (with the same people in charge), thereby making accountability and liability fixing very difficult if something were to go wrong further down the line.

She concludes that the story of event 142 is even worse than event EE1:

Once again, they are certainly hiding things that they dont want conscientious scientists and aware citizens to see and know.

Taken together, the two webinars highlighted how hybrid Bt cotton is being deceptively used as a template for rolling out GM food crops: a fraud being used to promote another fraud in order to force unnecessary GMOs into Indian agriculture.

See the original post:
From Cotton to Brinjal: Fraudulent GMO Project in India Sustained by Deception - CounterPunch

Before bacteria colonize a tissue in the human body, such as the intestine, they have to attach. Not only that, they have to achieve firm adhesion under hydrodynamic flow. New research reports a molecular mechanism behind an ultrastable protein complex responsible for resisting shear forces and adhering bacteria to cellulose fibers in the human gut. The results explain how gut microbes regulate cell adhesion strength at high shear stress through intricate molecular mechanisms including dual-binding modes, mechanical allostery, and catch bonds.

The researchers used single-molecule force spectroscopy (SMFS), single-molecule FRET (smFRET), and molecular dynamics (MD) simulations to uncover that two different binding modes allow bacteria to withstand the shear forces in the body. The findings are published in Nature Communications in the paper titled, High force catch bond mechanism of bacterial adhesion in the human gut.

Cellulose is a major building block of plant cell walls, consisting of molecules linked together into solid fibers. For humans, cellulose is indigestible, and the majority of gut bacteria lack the enzymes required to break down cellulose.

However, recently genetic material from the cellulose-degrading bacterium R. champanellensis was detected in human gut samples. Bacterial colonization of the intestine is essential for human physiology, and understanding how gut bacteria adhere to cellulose broadens our knowledge of the microbiome and its relationship to human health.

The bacterium under investigation uses an intricate network of scaffold proteins and enzymes on the outer cell wall, referred to as a cellulosome network, to attach to and degrade cellulose fibers. These cellulosome networks are held together by families of interacting proteins.

Of particular interest is the cohesin-dockerin interaction responsible for anchoring the cellulosome network to the cell wall. This interaction needs to withstand shear forces in the body to adhere to fiber. This vital feature motivated the researchers to investigate in more detail how the anchoring complex responds to mechanical forces.

By using a combination of single-molecule atomic force microscopy, single-molecule fluorescence, and molecular dynamics simulations, Michael Nash, PhD, assistant professor with joint appointments at the University of Basel, department of chemistry, and at ETH Zurich, department of biosystems science & engineering, along with collaborators from LMU Munich and Auburn University, studied how the complex resists external force.

Two binding modes allow bacteria to stick to surfaces under shear flow

They were able to show that the complex exhibits a rare behavior called dual binding mode, where the proteins form a complex in two distinct ways. The researchers found that the two binding modes have very different mechanical properties, with one breaking at low forces of around 200 piconewtons and the other exhibiting a much higher stability breaking only at 600 piconewtons of force.

Further analysis showed that the protein complex displays a behavior called a catch bond, meaning that the protein interaction becomes stronger as force is ramped up. The dynamics of this interaction are believed to allow the bacteria to adhere to cellulose under shear stress and release the complex in response to new substrates or to explore new environments.

We clearly observe the dual binding modes, but can only speculate on their biological significance. We think the bacteria might control the binding mode preference by modifying the proteins. This would allow switching from a low to high adhesion state depending on the environment, Nash explained.

By shedding light on this natural adhesion mechanism, these findings set the stage for the development of artificial molecular mechanisms that exhibit similar behavior but bind to disease targets. Such materials could have applications in bio-based medical superglues or shear-enhanced binding of therapeutic nanoparticles inside the body. For now, we are excited to return to the laboratory and see what sticks, said Nash.

Read the original here:
Bacterial Superglue Allows Adhesion to the Gut - Genetic Engineering & Biotechnology News

Nucleic acid isolation and purification is an initial step in molecular biology studies and recombinant DNA techniques. The process of isolation includes mechanical and chemical disruption, enzymatic digestion, while the purification involves combination of extraction/precipitation, chromatography, centrifugation, electrophoresis, and affinity separation.

View Report : https://www.transparencymarketresearch.com/nucleic-acid-isolation-purification-market.html

This technique has wide applications in the field of genetic engineering, life science research, forensics and molecular diagnostics. Nucleic acid isolation helps in processing of more sample in less time, minimizes nucleic acid loss ad degradation and increases laboratory efficiency and effectiveness. The purified product can thus be used in recombinant technology methods, and be used in targeted purposes in research.

The rising demand of pure nucleic acids in pharmaceutical and biotechnological industries, and growing use of nucleic acid-based tests in diagnosis have propelled the growth of this market across the globe. Moreover, increasing applications of these techniques in various fields such as genetic engineering, life science research, forensics and molecular diagnostics and government funding in R&Ds and the recent technological innovations are expected to fuel the growth of this market.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9521

In addition, emergence of new technologies in molecular diagnostics, expression analysis and genotyping would create an opportunity for the suppliers in future. However, low market penetration of automated nucleic acid isolation and purification procedures in developing countries, is a key factor restraining the growth of global nucleic acid isolation and purification market. Similarly, higher prices of the instruments associated with these procedures is one of the major challenges for this market. New product development, mergers and acquisition and partnership are some of the key trends in nucleic acid isolation and purification market.

The market is segmented into technology, application, product, end user, and geography. Based on various type of technology, the market can be segmented as: columnbased, magnetic bead-based, reagent-based, and other (anion exchange-based, glass fiber-based) for DNA and RNA isolation and purification. Column-based technology for DNA isolation and purification commands the largest share of the global market. Magnetic bead-based technologyis poised to grow at fastest rate.

Request For Covid19 Impact Analysis https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=9521

Application segments of this market includes genomic DNA isolation and purification, micro RNA isolation and purification, blood DNA isolation and purification, mRNA isolation and purification, plasmid DNA isolation and purification, total RNA isolation and purification, and PCR clean up. The plasmid DNA isolation and purification is the leading market segment by application. The end-users of the market are academic research, hospitals and diagnostic centers, pharmaceutical and biotechnology companies, contract research organizations, and other end users. Nucleic acid isolation and purification market have its major share in academic research organizations.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

North America holds the leading position in the Nucleic Acid Isolation and Purification market followed by Europe. Asia Pacific is the most promising market for the growth of market due to various emerging economies. The market in the region is easy to penetrate and it is expected to have a huge future scope in the region, especially India and China, so the players are looking invest more in Asia-Pacific region. Some of the key players in global Nucleic Acid Isolation and Purification Market are Agilent Technologies Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Danaher Corporation (U.S.), Illumina Inc. (U.S.), Life Technologies (U.S.), Promega Corporation (U.S.)., among others.

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-radiation-therapy-market-to-reach-us-8-6-bn-by-2026product-approvals-to-drive-growth-transparency-market-research-300998453.html

2.https://www.biospace.com/article/dna-test-kits-market-increase-in-demand-for-ancestry-testing-to-drive-market/

See more here:
Nucleic Acid Isolation and Purification Market : The Rescuer in COVID-19 Crisis, Says TMR - Owned

We are in front of computer screens more than ever before. What does that mean with staying eye healthy?

August is Children's Eye Health and Safety Month, perfectly positioned for parents as a reminder to add a visit to the optometrist to your back-to-school checklist. Only this year, eye safety is more important than ever before.

Because of the COVID-19 pandemic, kids and adults alike are spending more time in front of a computer screen than ever before. Children are taking school classes at home virtually, while many parents are still working from home. That means increased screen time, and the potential for eye damage if you're not careful.

"Any time youre spending more than two hours continuously staring at a screen, we are worried about digital eyestrain and discomfort," said Dr. Katherine White is an optometrist with Kirn Family Eye Care in Susquehanna Township, Dauphin County.

Dr. White suggests good eye health starts with a comfortable workspace. A chair with good back support will help prevent neck strain. A flat surface slightly below eye level for a laptop or computer kept about an arm's reach away will prevent digital eye strain, and ultimately keep you from getting headaches.

White recommends everyone working from home subscribe to the '20-20-20 rule': That's every 20 minutes, you should look across the room, at least 20 feet away, for about 20 seconds. If you can get outside, Dr. White says simply taking a break away from your screen will help eye sight. If not, try to rest your eyes for 15 minutes every two hours with no other screens around.

For kids, it is recommended they stop using electronics at least an hour before bed time. Doctor White says studies have shown the more screen time closer to bed, the tougher it is to fall asleep.

Symptoms such as dry eyes, irritation or burning, or headaches should be responded with a call to an optometrist and a visit to the eye doctor.

More here:
Eye health in a pandemic: Keeping vision safe with increased screen time - 13newsnow.com WVEC

The Subaru 2020 Levorg mid-size touring wagon was made available for pre-order last month and introduced a range of features such as a new 1.8-liter, four-cylinder engine and continuously variable automatic transmission (CVT). But perhaps the most exciting feature is on the safety front, as the car is the first in the Subaru fleet to contain the companys next-generation EyeSight ADAS technology.

The EyeSight stereo-based vision system assists with passenger safety with three key feature sets. Adaptive cruise control (ACC) optimizes vehicle speed during highway driving; lane keep assist (LKA) helps prevent cars from swerving out of their lane; and auto de-acceleration, pre-collision braking, and hands-off driving functionality monitor surrounding traffic and provide mechanisms for avoiding unintended acceleration, head-on collisions, and other serious accidents (Figure 1).

Figure 1. The EyeSight platform consists of two stereo cameras and accepts inputs from four radars positioned around the vehicle.

The EyeSight platform consists of two color stereo cameras mounted on the inside of the Levorgs windshield near the cars rearview mirror. The cameras, as well as four external radars, capture images of cars, pedestrians, lane dividers, traffic, etc., which the system then analyzes and, if needed, sends signals to various control systems like steering or brakes to take corrective action (Figure 2). These actions could include accelerating, decelerating, changing direction, flashing lights, honking, and other methods of alerting drivers of possible danger.

Figure 2. Subarus EyeSight Advanced Driver Assistance System (ADAS) uses stereo vision to help motorists avoid collisions, pedestrians, and other road hazards.

By being able to monitor traffic and take action in dangerous driving situations, the next-generation ADAS subsystem is essentially an extra pair of eyes on the road.

In developing its latest stereo vision-based ADAS technology, Subaru enlisted programmable processing vendor, Xilinx. The main compute engine on the Eyesight system is an ASIL-rated, 16 nm Zynq UltraScale+ multi-processor system-on-a-chip (MPSoC), which integrates a 64-bit Arm Cortex-A53 core, two Arm Cortex-R5 real-time cores, and programmable logic that provides hardware flexibility for a range of functions (Figure 3).

Figure 3. The Subaru EyeSight ADAS system is based on a Xilinx Zynq UltraScale+ MPSoC with multiple Arm cores and programmable logic fabric.

In the EyeSight system, the Zynq UltraScale+ MPSoC fuses data from four radar sensors on the Levorg; performs image detection, classification, and perception operations; and delivers that information to the Levorg braking system. The MPSoCs 16 nm process technology provides the performance needed for stereo processing of radar data and the conversion of that data into 3D point clouds (Figure 3).

Figure 3. The MPSoC in the EyeSight ADAS system process radar data and convert them into point clouds so that object detection algorithms can be applied.

The Zynq UltraScale+ MPSoCs Cortex-A53 subsystem handles real-time video, graphics, waveform, and packet processing, while the R5 cores and video codec unit (VCU) execute motor control, sensor fusion, wireless communication, and other multimedia tasks. Available as an automotive-grade platform with multiple power domains, the MPSoC delivers exceptional performance per watt operation as well as functional safety and security features.

Unlike common approaches, the image processing technology adopted in our new generation system scans everything captured by stereo cameras and creates high-precision 3D point clouds, enabling us to offer advanced features such as pre-collision braking at an intersection and assisting with hands-off driving in traffic congestion on a highway, says Tetsuo Fujinuki, CTO at Subaru. Because Xilinx automotive devices contain built-in capabilities that allow us to meet strict ASIL requirements, they are unquestionably the best technology to implement Subarus new ADAS vision system.

Subarus Eyesight technology received the highest IIHS rating in 2019-20, and is designed to provide drivers with safe and tested technology that can accurately react to driving scenarios. Of course, none of this is possible without advanced computational capabilities afforded by the automotive-grade Zynq UltraScale+ MPSoC.

The MPSoC is doing all of the detection, classification, and perception on the EyeSight, and providing input to the braking system. Its also doing sensor fusion of the radar inputs, says Willard Tu, Senior Director of Automotive at Xilinx. Everybody realizes that the more sensors you put on cars, the richer the fusion of data you get.

This is a super opportunity for programmable logic, he adds.

For more information, visit Xilinx website.

Tiera Oliver, edtorial intern for Embedded Computing Design, is responsible for web content edits as well as newsletter updates. She also assists in news content as far as constructing and editing stories. Before interning for ECD, Tiera had recently graduated from Northern Arizona University where she received her B.A. in journalism and political science and worked as a news reporter for the university's student led newspaper, The Lumberjack.

Read more from the original source:
Guess What's Under the Hood of the Subaru Levorg? ADAS and Programmable Logic - Embedded Computing Design

Vision Care Market analysis on the global market is an in-depth study that provides an arrangement of efficient market authenticities. The study shows statistics on the market status of the leading market players and offers key trends and opportunities in the market. The analysis of the global market begins with an industry-based framework and outlines the current information of the global market, complemented by current status records.

Vision care is the care and treatment of eyes, eyesight conditions, and vision. The exploding use of electronic devices for everyday functioning has also been related to eye disorders. In recent years, the use of technology has particularly increased among children. Studies suggest excessive use of electronic devices could lead to eye disorders. This indirectly is stoking demand for vision care products.

Ask for Sample Copy of This Report: https://www.theinsightpartners.com/sample/TIPRE00011953/

Top Key Players Profiled in This Report:

Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor, Johnson & Johnson, LUXOTTICA GROUP, Rodenstock, Safilo Group, ZEISS

The key questions answered in the report:

The vision care market is driving due to the rising geriatric population more susceptible to eye diseases and technological advances in eye care devices. Moreover, the raise awareness for eye health and to address vision-related problems is also serving to boost the vision care market.

Get Discount on This Report: https://www.theinsightpartners.com/discount/TIPRE00011953/

This research report represents a comprehensive overview of the competitive landscape of the Vision Care Market. Furthermore, it offers massive data relating to the recent trends, technological advancements, facts and figures, and methodologies. The research report analyzes the global market in a detailed and concise manner for better insights into the businesses.

Research studies have taken the help of graphical presentation techniques such as information graphics, charts, tables and diagrams. This Vision Care provides guidelines for both established players and new entrants in the market.

A detailed expansion of the Global Vision Care Market has been provided by applying industry analysis techniques such as SWOT analysis. Collectively, this research report provides a reliable assessment of the global market to present the overall structure of the businesses.

Interested in Purchasing this Report Click @ https://www.theinsightpartners.com/buy/TIPRE00011953/

Some Points of Table of Contents:

Chapter 1. Introduction

Chapter 2. Vision Care Market Key Takeaways

Chapter 3. Research Methodology

Chapter 4. Global Vision Care Market Market Landscape

Chapter 5. Global Vision Care market Key Market Dynamics

Chapter 6. Vision Care Market Global Analysis

Chapter 7 to 9. Detail Market Segmentation

Chapter 10. Impact Of COVID-19 Pandemic On Global Rare Neurological Diseases Treatment Market

Chapter 11. Vision Care Market Industry Landscape

Chapter 12. Company Profiles

Chapter 13. Appendix

About Us:

The Insight Partners offer our clients an opportunity to customize our off the shelf syndicated reports at no additional cost. This provides our clients with precise intelligence they require in turn saving them thousands of dollars in commissioning large consulting studies. The Insight Partners specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact:

Contact Person: Sameer Joshi

Phone: +1-646-491-9876

Email ID: [emailprotected]

Website: http://www.theinsightpartners.com

Read the rest here:
Vision Care Market Covid-19 Scenario, Growth Opportunities, And Forecast 2027 | Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor - Scientect

11-year-old George has found a new family.

11-year-old George was rescued when he was a young stray.

Sadly, his owner died and he was taken to Cats Protection on Gildersome Lane in Morley.

While there he had a routine vet appointment where they found cancer in his eye.

Unfortunately, his eye had to be removed.

Luckily, George has now found his forever home.

He has been adopted by Kate, from Gildersome, who is partially sighted due to her Usher syndrome diagnosis.

Usher syndrome is a degenerative condition that causes hearing and vision loss.

Kate said: I saw George on the Cats Protection website and, having begun to lose part of my sight in the past few years, I immediately fell in love with this gorgeous chap.

Having only one eye certainly hasnt held him back.

He loves joining us for story time with my five-year-old daughter, and, while he prefers to stay close to home, hes been out walking along fences and climbing trees.

Due to coronavirus restrictions, Kate could not visit George before he was adopted, instead getting to know him through videos.

She said: George was delivered directly to our door and he settled in straight away, following us around and giving us cuddles."

Cats Protection rehoming and welfare assistant Diane Armer said: George was particularly popular with everyone at the centre, he has such a fantastic personality.

It is so lovely to hear that George has settled in so well.

A message from the Editor: Leeds has a fantastic story to tell - and the Yorkshire Evening Post has been rooted firmly at the heart of telling the stories of our city since 1890. We believe in ourselves and hope you believe in us too. We need your support to help ensure we can continue to be at the heart of life in Leeds. Subscribe to our website and enjoy unlimited access to local news and information online and on our app. With a digital subscription, you can read more than 5 articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Click here to subscribe. For more details on our newspaper subscription offers click here.

Here is the original post:
Cat who lost eye to cancer finds forever home with partially sighted owner in Leeds - Yorkshire Evening Post

"CooperVision received FDA-approval of the MiSight 1 day contact lens on Nov. 15, 2019, making the United States our 18th market worldwide. This reinforced CooperVision as a leader in the myopia management category," said Daniel G. McBride, President of CooperVision. "In this particular moment in time, with so many children learning virtually and spending less time outdoors, the topic of myopia management is more relevant than ever before. As category creators and leaders in the myopia management sector, we believe it is our responsibility and privilege, alongside the optometric community, to educate parents and offer them tools to help their children who may be struggling with myopia. Our decision to make this sizable investment in educating parents is consistent with our view that addressing myopia early is vitally important."

This new, multichannel direct-to-consumer advertising campaign featuring Gellar will highlight the importance of annual comprehensive eye exams in monitoring the progression of myopia in children. The campaign will include national and regional broadcast segments, content across digital and social media, and influencers who will be sharing their personal experiences with myopia. In addition, CooperVision will be collaborating with the National Association of School Nurses(NASN) to engage in meaningful unbranded conversations about myopia with the organization's members. While the NASN does not endorse products, school nurses are often the first to observe the signs of myopia in affected children and are therefore important myopia management advocates.

"My husband and I are both nearsighted and our myopia has continued to worsen over time," said Gellar. "We want our kids to have a chance for better vision and lower their risk for future eye health issues. While regular eyeglasses or contacts help children see a whiteboard or tennis ball today, MiSight 1 day lenses offer children the benefits of clear vision while slowing myopia progression during their growing years*. That is why I am thrilled to be partnering with CooperVision on this campaign."

"CooperVision has always been committed to eye health innovation," said Jerry Warner,Executive Vice President, Americas and Global Commercial Functions of CooperVision. "The goal of this campaign is to help build awareness of the short and long term effects of myopia. More than just vision correction, CooperVision's myopia management program can help build a brilliant future for our children."

To learn more, visit https://coopervision.com/practitioner/myopia-management

* Indications for use: MiSight 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Compared to a single vision 1 day lens over a 3 year period.

References:1Chamberlain P, et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019; 96(8): 556-567.2Holden BA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-42.3Cooper Y. (2019, May 1). With Childhood Myopia Rates on the Rise, the American Optometric Association Highlights the Importance of Early Intervention through Annual Eye Exams. Retrieved from https://www.aoa.org/newsroom/myopia-rates-on-the-rise-syvm.4CooperVision data on file 2019. Myopia Awareness, The Harris Poll online survey 6/27/19 to 7/18/19 of n=313 ECPs (who see at least 1/month myopic child, age 8-15) in U.S. Slightly or significantly increased.5CooperVision data on file 2019. Myopia Awareness, The Harris Poll online survey 6/27/19 to 7/18/19 of n=313 ECPs (who see at least 1/month myopic child, age 8-15) in U.S. ODs (89%) and MDs (68%) strongly/somewhat agree.6Xu L, Wang Y, Wang S, Wang Y Jonas JB. 'High Myopia and Glaucoma Susceptibility: The Beijing Eye Study. Ophthalmology, 2007;114(2):216-20.7Flitcroft DI. The complex interactions of retinal, optical, and environmental factors in myopia aetiology Prog Retin Eye Res. 2012;31(6):622-660.8Chen SJ, et al. Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai eye study. Invest Ophthalmol Vis Sci. 2012;53(8):4868-4873.9Chen SJ, et al. High myopia as a risk factor in primary open angle glaucoma. Int J Ophthalmol. 2012; 5(6):750-753.10 Younan C, et al. Myopia and incident cataract and cataract surgery: the blue mountains eye study. Invest Ophthalmol Vis Sci. 2002;43(3625-3632).

About CooperVisionCooperVision, a division of CooperCompanies (NYSE:COO), is one of the world's leading manufacturers of soft contact lenses. The Company produces a full array of daily disposable, two-week and monthly contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism, presbyopia and childhood myopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visitwww.coopervision.com.

About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units,CooperVisionandCooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visitwww.coopercos.com.

Media Contacts

Consumer Media: EvolveMKD, [emailprotected] or +1-646-517-4220

Eyecare, Medical and Science Media: McDougall Communications,[emailprotected] or +1-585-478-4338 (mobile)

SOURCE CooperVision

https://coopervision.com

Visit link:
CooperVision Announces Sarah Michelle Gellar as Spokesperson to Increase Awareness of Myopia Management and the Brilliant Futures Program with MiSight...

A HEALTHY 11-year-old girl can no longer string a sentence together after being diagnosed with dementia.

Molly Ingham was diagnosed with a rare form of childhood dementia in May last year after she started to lose her eyesight, memory and mobility.

5

5

The normal outgoing little girl started having seizures when she was just six-years-old.

Batten disease robs children of their speech and sufferers of the disease rarely make it to adulthood.

Mum Adele Ingham, 39, said Molly can become confused because of the condition and now has to use a wheelchair as she no longer has any balance.

She said: "It's been devastating to watch the most outgoing little girl that could do everything every other six-year-old could do go into this situation.

It's soul destroying. It affects short term memory so she won't take in new things.

She started a special school last September and made lots of friends but she can't remember any of their names now.

What is Batten disease?

Batten disease, otherwise known as Neuronal Ceroid Lipofuscinoses, is a fatal disorder that affects the nervous system.

The condition, which typically begins in childhood, can manifest itself in vision problems and seizures.

It can then worsen, with children suffering from cognitive impairment, worsening seizures, and progressive loss of sight and motor skills.

It is often fatal by late teens or early 20s.

According to BDFA UK, an estimated 1 3 children are diagnosed with an infantile form of the disease each year, meaning there are probably between 15 and 30 affected children in the UK.

There are other variations of the genetic disease, with 14 strains so far diagnosed.

There is currently no cure

5

The family live in Stalybridge, Greater Manchester and Adele said Molly has started to ask her when she can go home, but she asks the question when they are already home.

She added: There's a lot of confusion.

"My dad died two and a half years ago and she still wants to go in when we drive past his flat.

She used to know every word to every Disney song now she can't even string a sentence together.

"She can't see anymore. I just bought her a new Olaf toy and she didn't know what it was until she felt his carrot nose.

5

Molly used to be able to ride scooters, go to the park and use the climbing frames - like any other child, but now things have changed.

"Everything just started becoming more difficult so now she's in a wheelchair because she's got no balance and she'll fall and hurt herself.

I might have only a few years left with her and that's being positive.

Adele said Molly was a perfectly healthy child until she turned six when teachers started to notice her zoning out and she began having seizures.

Soon after Molly was taken to see a paediatrician who suggested ADHD or a low IQ but after a second opinion, she was diagnosed with absence epilepsy until the condition progressed and her seizures became more frequent.

5

CLASS ACTBack-to-school with the Radfords as they share how to get 22 kids organised

Exclusive

ALL WHITEI wed in a 20 dress which I found stained on the shop floor - a wash sorted it

PLASTIC PRIVATESWe saved up for 'Barbie surgery' because we hated how we looked down below

FROZEN IN TIMEI've been looking after my '10-month-old' daughter for the last 19 years

NO KIDDINGI get viciously shamed for dumping my kids on my parents- but I need the break

THAT'S RADMum-of-22 Sue Radford jokes about Millie's 'mum tum' as they pack hospital bag

Adele worries she doesn't have much time left with Molly and is currently waiting to find out if her daughter has been accepted for a treatment trial in the US.

The mum and daughter would have to travel to Dallas to a centre called Taysha Gene Therapy.

The cost would be covered by the company as its a trial but the spaces are limited.

Adele added: "The treatment won't bring her eyesight back but it might help her to say the odd sentence instead of the odd word so there's still hope and a lot of fighting to do but I won't stop."

Read the original:
Our perfectly healthy daughter can no longer string a sentence together after being diagnosed with dementia - The Sun

The parents of a girl battling a deadly blood disorder are begging people to join the stem cell donor register to save her life after her only match in the world pulled out at the last minute.

Evie Hodgson, eight, who suffers from aplastic anaemia, was due to have a bone marrow transplant this month but her donor backed out at the last possible moment.

Her mum, Tina, says the chances of finding another donor are so slim that doctors are now planning a different course of treatment. But, in future, a stem call transplant is Evies best hope of being cured.

The schoolgirl, from Whitby, North Yorks, was first taken to hospital with a rash and was diagnosed with aplastic anaemia in May.

After a global donor search was launched, a 10/10 match was found and the anonymous donor agreed to the procedure. In preparation, Evie had to have dental work and one of her ovaries was removed. But on August 14 the donor pulled out.

Tina, 37, who works at RAF Flyingdales, in Pickering, North Yorks, said: We were devastated, it was a huge blow. We have no idea why the donor changed their mind. Evie has already been through so much. She thought she had a donor and now she doesnt.

The donor pulling out is quite hard-hitting, but we want to raise awareness of the stem cell register. Its so easy to be a donor. Its just like giving blood, but you could save a childs life. Its so easy to join but only 1% of the UK population is registered.

Evie said: I need this transplant to save my life. Please sign the register to help.

Tina added: The condition Evie has is life-threatening. She wont survive without a transplant. We are desperately appealing for people to sign the stem cell register.

Evie was diagnosed with the condition after she developed a pin-prick rash on her back, which didnt fade. Tests revealed she had low blood platelet levels and she was told she needed a bone marrow transplant.

Aplastic anaemia is a rare life-threatening condition where the bone marrow fails to produce enough blood cells. Around 100-150 people are diagnosed in the UK each year.

Treatment can include immunosuppressants, chemotherapy, blood transfusions, or blood and bone marrow transplants.

Neither Tina, dad Andy, 49, or brother William, five, were a match and so an international search was launched.

Tina said: Our world crumbled when Evie was diagnosed. Evie knew shed need chemotherapy. She donated her hair to The Little Princess Trust, after making friends with poorly children who have lost all their hair.

Evie will be treated with immunosuppressants while the search for a donor continues.

Blood cancer charity Anthony Nolan is looking for stem cell donors between the ages of 16-30.

Research shows that younger donors result in better outcomes for patients.

To find out how to donate click here.

View original post here:
Parents plea for stem cell help to save life of daughter with rare blood disorder - Mirror Online

It was about the 3rd week into Bastions recovery from his TPLO surgery and he was already having a rough time. Bastion was a gregarious yellow Labrador who had his injured stifle about 25 days ago. Fortunately, his family elected for him to have his stifle surgically reconstructed. Initially, he had recovered well from surgery. But one day in particular, he presented to the hospital because he had a brief setback. He was limping far more severely than what would be normally expected at this stage of recovery.

The osteotomy from his surgery had not yet completely healed and he was still in the middle of his prescribed 5 weeks of exercise strict restriction. His family was trying their best but Bastion wasnt having it. He was too active at home and his humans were growing frustrated. Anti-anxiety medications had been dispensed but they were not given. Instead, his family had decided to give him CBD oil at home. When I asked why the prescribed medications had not been given, the client responded, I found CBD oil at the local farmers market and I figured it would work just as well.

Like Bastion, an increasing number of pets are receiving cannabidiol (CBD) supplements. The popularity of CBD continues to rise and many clients are incorporating CBD as part of the medication protocol for their pets, either as an adjunct or, as alternative treatment option.

Perhaps the initial interest in the benefits of CBD can be traced back to 1998, or possibly earlier, when scientists at the National Institutes of Health discovered that CBD could protect cells from oxidative stress. These findings fueled interest in the human medical field and, in large part, that appeal has been transmuted into veterinary medicine. The regard for this molecule has risen to such levels that in many homes, CBD is being used as the sole treatment option for a variety of medical conditions.

Veterinarians are becoming more fluent in the fascinating pharmacology regarding the use of this phytocannabinoid. A recent survey indicated that most veterinarians (61.5%) felt comfortable discussing the use of CBD with their colleagues, but only 45.5% felt comfortable discussing this topic with clients.1 Furthermore, veterinarians and clients in states with legalized recreational marijuana were more likely to talk about the use of CBD products to treat canine ailments than those in other states.2 Lastly, CBD was most frequently discussed as a potential treatment for pain management, anxiety and seizures.1 At first glance, the use of CBD has tangential or limited relevance in the world of veterinary surgery. However, as one takes a closer look at the putative, and proven benefits, it is clear that we are just scratching the surface of its therapeutic benefits. This article takes a brief dive into the world of CBD and its promise in the field of veterinary surgery.

Pain

Whether you perform surgery within a specialty discipline (oncology, orthopedics, neurology, soft tissue surgery, mixed animal, oral/dental, etc), or surgery is only a small part of your general practice, every veterinarian endeavors to aggressively manage pain. The first choice for pain relief among many clinicians are the medications that have been more extensively studied including, but not limited to, anti-inflammatories, gabapentinoids, opioids, local anesthetics, and other analgesics (acetaminophen, amantadine, cerenia etc). These medications or a combination thereof, have been prescribed to treat pain from orthopedic surgery, soft tissue surgery, surgical neuropathic conditions, pain from intestinal surgery, to name just a few. In the most basic schema, pain is divided into four categories: nociceptive pain (a response to damaged tissue), neuropathic pain (a response to directly-damaged sensory or spinal nerves), centralized pain (the result of pain signals being improperly amplified), and inflammatory pain.1 Cannabinoids may have a role to play in mediating all four of these types of pain states. When tissue is damaged, histamine, serotonin, TNF-alpha, IL-1-beta, IL-6, and Il -17 6, and interleukin 17 are released.2 Cannabinoids bind to the CB1 receptors and attenuate the pain signal by slowing down the release of those neurotransmitters.3 This process can take place locally or in the central nervous system.3 Cannabinoids have also been shown to inhibit the release of GABA, a well known neurotransmitter associated with pain.3 Although there is a paucity of clinical research on the use of CBD to treat postoperative pain in the veterinary medical setting, there has been heartening research conducted in humans. Indeed, National Academies of Sciences, Engineering, and Medicine concluded that there is, substantial evidence that cannabis is an effective treatment for chronic pain in adults.

Opioids have long been the go to option, or cornerstone of pain management, however, the potential for the adverse events associated with the use of opioids in veterinary patients is universally accepted.38 I have seen how distressing it can be for a family to see their pet experiencing any of the unpleasurable side effects of opioids including urine retention, delayed bowel movements, whining, panting, disorientation, or other manifestations of dysphoria. Those are just some of the challenges that clinicians face when using opioids for chronic pain management. Considering the ongoing consequences of the opioid epidemic, there is a search for pain management solutions that are innovative, prone to less adverse events, and are more effective. As the scientific community begins to evaluate the evidence for use of CBD , it is clear that more research is needed.

Anecdotal reports of CBDs efficacy as a pain reliever are ubiquitous but more are turning to scientific data for evidence of CBDs efficacy. A study in 2020 evaluating effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients found that over half of chronic pain patients (53%) reduced or eliminated their opioids within 8 weeks after adding CBD-rich hemp extract to their regimens.5 Almost all CBD users (94%) reported quality of life improvements.5 And in a recent study evaluating orally consumed cannabinoids for long-lasting relief of allodynia in a mouse model, found that cannabinoids reduced hyperalgesia and a similar effect was not found with morphine.4 Mouse vocalizations were recorded throughout the experiment, and mice showed a large increase in ultrasonic, broadband clicks after sciatic nerve injury, which was reversed by THC, CBD, and morphine.4 The study demonstrated that cannabinoids provide long-term relief of chronic pain states.4 If research shows that use of cannabinoids in animals, specifically, CBD, can help to decrease the use of opioids for pain management, that would help make more animals comfortable and potentially help to fight the tragic epidemic of human prescription opioid abuse. Further research is needed in a variety of species, specifically, both the canine and feline species.

Bone Healing

Both general veterinary practitioners and veterinary surgeons commonly diagnose and treat fractures. A large retrospective study of fracture incidence in dogs in North America has not been published since 1994; however, the findings from that study are still informative regarding the frequency of bone injuries. That study demonstrated that approximately 24% of all patients in the population studied over a 10 year period were affected by a disorder of the musculoskeletal system, with fractures contributing the largest proportion (over 29%) of all of the diagnosis of the appendicular skeletal system.7 Although that research is dated, the conclusions from this study - at the very least, indicate that fractures are commonplace in the clinical veterinary setting.7 Fracture repair has gradually become more straightforward due to improvements in technology. Because of these innovations, speciality surgeons and general practitioners who repair fractures have begun to see better surgical outcomes. So whether you primarily stabilize fractures with implants, or if external coaptation of fractures with the intention to refer (or perhaps as the primary means of fixation) is your treatment of choice, all veterinary practitioners aim to help fractured bones heal quickly. Despite these technological improvements, bone healing can be protracted or non existent with some fractures. There are a variety of options at a veterinarians disposal to kick-start the healing process but perhaps in the near future, CBD may be added to that armamentarium. The effect of CBD in fracture healing has been investigated evaluating bone callus formation in femur fractures in a rat model.8 The findings demonstrated enhanced biomechanical properties of healing fractures in those given CBD compared with a control group.8 This effect was not found in those only given 9-THC. Moreover, the bone forming effects (osteogenic) of CBD were weakened when test subjects were given equal amounts of CBD and 9-THC.6 Another in vivo research study indicated that when CBD is incorporated into a surface that promotes bone growth (osteoconductive scaffold) it can stimulate stem cell migration and osteogenic differentiation.9 Further studies are needed to better evaluate the role of CBD in healing and bone metabolism of companion animals so that these findings can be applied in the clinical setting.

Additionally, cannabis has been shown to be a useful addition in treatment plans optimized to improve bone health in laboratory studies. A study endeavored to more closely understand the role of CB2 receptors in maintaining bone health. CB2 receptors in bone cells have been linked to maintaining bone density and stimulating growth, and may therefore have a part in reversing the effects of osteoporosis.10 One study evaluating role of CB2 receptors, found that in mice whose genes had been altered to remove the CB1 or CB2 receptors, those that developed signs of bone weakness that were far more pronounced than those in the control group.12 Another study in 2009, investigated the relationship between CB2 expression and bone disease in humans. The study found that people with dysfunctional CB2 receptors to have significantly weaker hand bones.11

Arthritis

Osteoarthritis (OA) affects many dogs, large and small. Most often, OA is the consequence of a developmental orthopedic disease that often affects a single joint or a pair of joints, and, less often, affects multiple joints. It is axiomatic that Mother Nature likes symmetry thus developmental orthopedic diseases frequently affect both left and right joints. For example, hip dysplasia is reportedly bilateral in >60% of affected dog,s13 and elbow dysplasia is bilateral in approximately 50% of affected dogs.14 Osteoarthritis occurs secondary to a myriad of primary orthopedic conditions that affect a variety of joints including: the hip (most common causes of OA in the hip: hip dysplasia, Perthes disease); stifle (patellar luxation, cranial cruciate ligament disease, osteochondritis dissecans [OCD]); elbow (elbow dysplasia, elbow OCD, fragmentation of the medial coronoid process, incomplete ossification of the humeral condyle); shoulder (shoulder OCD, developmental shoulder subluxation); tarsus (OCD of the talus), and carpus (carpal laxity, carpal subluxation secondary to chondrodystrophy); and metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joint degenerative osteoarthritis (digital osteoarthritis) .

Cannabinoids were found to treat pain secondary to inflammation in a variety of studies on humans. Some of the most compelling research has shown that cannabis can reduce the inflammation in the joint caused in human patients diagnosed with immune mediated arthritis.15 One study found that cannabinoids could simultaneously reduce the secretion of cytokines involved in inflammation from one type of TH immune cells, which were being under-produced, while also increasing their numbers to correct their scarcity.15 Furthermore in a study in 2003, researchers found that plant-based cannabinoids could suppress the expression of interleukin-1betaone of the most prominent markers for inflammation in patients with rheumatoid arthritisby as much as 50%.16 And finally, in 2006, transdermal applications of CBD were shown to decrease biomarkers that can contribute to neurogenic inflammation in a sample of arthritic rats. 17

A report published in the journal of PAIN, lead by researchers at Baylor College of Medicine revealed the results of a large, double blinded, placebo controlled study on the positive effects CBD had in the fight against osteoarthritis.18 The study was designed with two main goals: The first portion of the research studied the effect CBD had on the inflammatory molecules and cells in mice.18 The second portion of the study, investigated whether CBD improved the quality of life in dogs diagnosed with osteoarthritis. In lab tests and in mouse models, CBD significantly decreased the production of natural chemicals that promote inflammation and it increased the natural chemicals that fight inflammation.18 Essentially, what they saw was a drop in proinflammatory cytokines and an increase in anti-inflammatory cytokines. 18 For dogs with osteoarthritis, CBD significantly decreased pain and increased mobility in a dose-dependent fashion. Importantly, A lower dose of liposomal CBD was as effective as the highest dose of nonliposomal CBD, indicating that the effect of CBD was quicker and more effective when CBD was delivered encapsulated in liposomes than without.18 Blood samples indicated no significant harmful side effects, or adverse events, over the 4-week analysis period.18 Although this study is very promising and it supports the safety and therapeutic potential of hemp-derived CBD for relieving arthritic pain in dogs, it is important to consult with your pets veterinarian before giving any supplement or medication.

In the veterinary population, use of cannabidiol and other alternative treatments may have the potential to obviate the need for other medications, and thus spare patients from adverse effects associated with their use. More likely, the use of cannabinoids could be additive or synergistic in a multimodal treatment strategy and could increase quality-of-life issues associated with painful arthritic conditions.

Intervertebral Disk Disease

As our patients age, discs in the spine also undergo degenerative changes. Thus, degeneration of intervertebral discs is evitable. This process of degeneration is multifactorial process and it involves hypoxia, inflammation, neoinnervation, accelerated catabolism, and reduction in water and glycosaminoglycan content.39 The magnitude and severity of disc degeneration can vary widely between patients. The most common locations of clinically relevant disc disease are located in the cervical spine, thoracolumbar spine, and the lumbosacral spine.40 Although there are various manifestations of disc disease, broad classifications of Hansen Type I and Type II are typically used to describe the condition. In short, disc material may either extrude (acute herniations) or protrude (chronic herniations), both of which compress the spinal cord which ultimately can cause pain, paresis, paralysis and other neurological deficits.40 The prevalence of thoracolumbar disc disease dogs has been estimated at 3.5%.40 Depending on the neurologic examination, diagnosis, severity, prognosis, and other factors, surgery may be recommended to decompress the spinal cord.

After surgical decompression, there are a host of challenges that the the patient, the family, and the surgeon, may have to work through including a potentially protracted recovery, recurrence of neurological signs, post surgical pain, spinal instability, urinary disorders, (cystitis, urinary tract infection, urinary retention, micturition disorders), ascending myelomalacia, and others.41 Could CBD play a part in helping to improve those affected by disc disease pre-, intra-, or post-operatively and what types of spinal disorders could benefit from CBD? A study conducted on the use of CBD in mice with degenerative disc disease showed promise in mitigating the effect of disc damage and wear.19 Instead of being ingested orally, CBD was injected at the site of the disc. Researchers investigated the effects of cannabidiol intradiscal injection using a combination of MRI and histological analyses.19 A puncture was created in the disc and then CBD was injected into the disc (30, 60 or 120 nmol) shortly after.19 The effects of intradiscal injection of cannabidiol were analyzed within 2 days by MRI.17 Fifteen days later, the group that received cannabidiol 120 nmol was resubmitted to MRI examination and then to histological analyses after the cannabidiol injection.19 What they found was that cannabidiol significantly decreased the effects of disc injury induced by the needle puncture.19 These results suggest that this compound could be useful in the treatment of intervertebral disc degeneration perhaps using a novel route of administration.

Unfortunately, the exact mechanism for how CBD oil helped protect disc damage is still being investigated. The hope is that the neuroprotective properties of cannabidiol can also be found in the study of canine and feline disc disease to ultimately improve functional recovery.

References:

Kogan L, Schoenfeld-Tacher R, et al. US Veterinarians' Knowledge, Experience, and Perception Regarding the Use of Cannabidiol for Canine Medical Conditions. Front Vet Sci. 2018;5:338.

Abd-Elsayed A., Deer T.R. (2019) Different Types of Pain. In: Abd-Elsayed A. (eds) Pain. Springer, Cham. https://doi.org/10.1007/978-3-319-99124-5_3

Manzanares J, Julian MD, Carrascosa A. Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes Curr Neuropharmacol. 2006 Jul; 4(3): 239257.

Abraham AD, Leung EJ, Brenden A, Wong BA, Rivera ZM, Kruse LC, et al. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. 2020 Jun;45(7):1105-1114. doi: 10.1038/s41386-019-0585-3. Epub 2019 Dec 7.

Capano A, Weaver R, Burkman E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. Postgrad Med. 2020 Jan;132(1):56-61. doi:10.1080/00325481.2019.1685298. Epub 2019 Nov 12.

Abraham AD, Leung EJ, Wong BA, Rivera ZM, Kruse LC, Clark JJ, Land BB. Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain. Neuropsychopharmacology. 2020: 45:11051114.

Johnson, J., Austin, C., & Breur, G. Incidence of Canine Appendicular Musculoskeletal Disorders in 16 Veterinary Teaching Hospitals from 1980 through 1989. Veterinary and Comparative Orthopaedics and Traumatology, 07(02), 5669. (1994). doi:10.1055/s-0038-1633097

Kogan NM, Melamed E, Wasserman E. Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts J Bone Miner Re. 2015 Oct;30(10):1905-13. doi: 10.1002/jbmr.2513. Epub 2015 May 10.

Kamali, A., Oryan, A., Hosseini, S., Ghanian, M. H., Alizadeh, M., Baghaban Eslaminejad, M., & Baharvand, H. Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Materials Science and Engineering: (2019). C, 101, 6475. doi:10.1016/j.msec.2019.03.070

Bab I, Zimmer A. Cannabinoid Receptors and the Regulation of Bone Mass. British Journal of Pharmacology. 2007 153:182-188 doi:10.1038/sj.bjp.0707593

I. Idris, A. Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Current Neuropharmacology. 2010. 8(3), 243253. doi:10.2174/157015910792246173

Meliha Karsak et al. The Cannabinoid Receptor Type 2 (CNR2) Gene Is Associated with Hand Bone Strength Phenotypes in an Ethnically Homogeneous Family Sample. Human Genetics. 2009. 5:629-36 doi:10.1007/s00439-009-0708-8.

Loder, R. T., & Todhunter, R. J. The Demographics of Canine Hip Dysplasia in the United States and Canada. Journal of Veterinary Medicine. 2017 115. doi:10.1155/2017/5723476

ONeill DG, Brodbelt DC, Hodge R,. Church DB, Meeson RL. Epidemiology and clinical management of elbow joint disease in dogs under primary veterinary care in the UK. Canine Medicine and Genetics. 2020 volume 7:1

Susan H. Pross et al. Differential Suppression of T-cell Subpopulations by THC (delta-9- tetrahydrocannabinol). International Journal of Immunopharmacology 12, no. 5 (1990): 539-44. doi:10.1016/0192-0561(90)90118-7

Robert B. Zurier et al. Suppression of Human Monocyte Interleukin-1 Production by Ajulemic Acid, a Nonpsychoactive Cannabinoid. Biochemical Pharmacology. 2003 4:649-55. doi:10.1016/s0006-2952(02)01604-0.

D.c. Hammell et al. Transdermal Cannabidiol Reduces Inflammation and Pain-related Behaviours in a Rat Model of Arthritis. European Journal of Pain. 2015 6:936-48. doi:10.1002/ejp.818

Verrico, C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Halpert, M. M. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. 2020. Pain. doi:10.1097/j.pain.0000000000001896

Silveira, J. W., Issy, A. C., Castania, V. A., Salmon, C. E. G., Nogueira-Barbosa, M. H., Guimares, et al. Protective Effects of Cannabidiol on Lesion-Induced Intervertebral Disc Degeneration. 2014. PLoS ONE 9:12 doi:10.1371/journal.pone.0113161

Yam, M., Loh, Y., Tan, C., Khadijah Adam, S., Abdul Manan, N., & Basir, R. . General Pathways of Pain Sensation and the Major Neurotransmitters Involved in Pain Regulation. International Journal of Molecular Sciences. 2018 19(8), 2164. doi:10.3390/ijms19082164

Costigan, M., Scholz, J., & Woolf, C. J. Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage. Annual Review of Neuroscience. 2009 32(1), 132. doi:10.1146/annurev.neuro.051508.135531

Arora A, Taliyan R, Sharma PL. Ameliorative Potential of Cannabis Sativa Extract on Diabetes Induced Neuropathic Pain in Rats. International Journal of Pharmaceutical Sciences and Research 1. 2010 https://www.researchgate.net/publication/216536386_Ameliorative_potential_of_cannabis_sativa_extract_

Mark S. Wallace et al., Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy. 2015. Pain 16(7): 616-27 doi:10.1016/j.jpain.2015.03.008.

Gruen, M. E., Roe, S. C., Griffith, E., Hamilton, A., & Sherman, B. L.. Use of trazodone to facilitate postsurgical confinement in dogs. Journal of the American Veterinary Medical Association. (2014) 245(3), 296301. doi:10.2460/javma.245.3.296

Serra, G., & Fratta, W. A possible role for the endocannabinoid system in the neurobiology of depression. Clinical Practice and Epidemiology in Mental Health. 2007. 3(1), 25. doi:10.1186/1745-0179-3-25

Kim, E. J., Pellman, B., & Kim, J. J. Stress effects on the hippocampus: a critical review. Learning & Memory. 2015. 22(9), 411416. doi:10.1101/lm.037291.114

Demirakca, T., Sartorius, A., Ende, G., et al. Diminished gray matter in the hippocampus of cannabis users: Possible protective effects of cannabidiol. 2010. Drug and Alcohol Dependence. doi:10.1016/j.drugalcdep.2010.09.020

Mateus M. Bergamaschi et al. Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Nave Social Phobia Patients. Neuropsychopharmacology. 2011 36(6):1219-26 doi:10.1038/npp.2011.6.

Jos Alexandre S Crippa et al. Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: A Preliminary Report. Journal of Psychopharmacology. 2010. 25: 1doi:10.1177/0269881110379283.

National Academies of Sciences, Engineering, and Medicine, 120.

Zieba, J., Sinclair, D., Sebree, T., Bonn-Miller, M., Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP1-independent mechanism. Pharmacology Biochemistry and Behavior. 2019. doi:10.1016/j.pbb.2019.05.002

Pamplona, F. A., da Silva, L. R., & Coan, A. C. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. 2018. Frontiers in Neurology, 9. doi:10.3389/fneur.2018.00759

Palmieri B, Laurino C, Vadal M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Mar-Apr 2019;170(2):e93-e99. doi: 10.7417/CT.2019.2116.

Sangiovanni, E., Fumagalli, M., Pacchetti, B., Piazza, S., et al.. Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. (2019). Phytotherapy Research. doi:10.1002/ptr.6400

B. Van Klingeren and M. Ten Ham. Antibacterial Activity of 9-tetrahydrocannabinol and Cannabidiol. 1976. 42(1-2): 9-12 doi:10.1007/bf00399444.

Giovanni Appendino et al. Antibacterial Cannabinoids From Cannabis Sativa: A StructureActivity Study. 2008. Journal of Natural Products 71(8):1427-430, doi:10.1021/np8002673

McIver, V., Tsang, A., Symonds, N., Perkins, N., et al. Effects of topical treatment of cannabidiol extract in a unique manuka factor 5 manuka honey carrier on second intention wound healing on equine distal limb wounds: a preliminary study. 2020. Australian Veterinary Journal. doi:10.1111/avj.12932

White, D. M., Mair, A. R., & Martinez-Taboada, F. Opioid-free anaesthesia in three dogs. Open Veterinary Journal. 2017 7(2), 104. doi:10.4314/ovj.v7i2.5

Hansen T, Smolders LA, Tryfonidou MA, et al: The Myth of Fibroid Degeneration in the Canine Intervertebral Disc: A Histopathological Comparison of Intervertebral Disc Degeneration in Chondrodystrophic and Nonchondrodystrophic Dogs. Vet Pathol 2017 Vol 54 (6) pp. 945-952.

40. Jeffery ND, Levine JM, Olby NJ, et al: Intervertebral disk degeneration in dogs: consequences, diagnosis, treatment, and future directions. J Vet Intern Med 2013 Vol 27 (6) pp. 1318-33.

41. Balducci F, Canal S, Contiero B, et al: Prevalence and Risk Factors for Presumptive Ascending/Descending Myelomalacia in Dogs after Thoracolumbar Intervertebral Disk Herniation. J Vet Intern Med 2017 Vol 31 (2) pp. 498-504.

See the article here:
Unraveling the use of CBD in veterinary medicine - Jill Lopez

Global Marketers offers newly published research report titled, Stem Cell Banking Market .This report focuses on delivering the up-to-date and latest growth opportunities, 360-degree market overview, and statistical data of Stem Cell Banking industry. The report highlights industry overview, growth trajectory, market dynamics, market share analyzed in detail this report. It furthermore gives a total synopsis of the market over the globe, including definitions, and applications. Moreover, the improvement plans and policies concerning the market have been discussed in the statistical surveying report, alongside the cost structures and production processes.

Get Free Sample copy @ https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#request_sample

The most significant players coated in global Stem Cell Banking Market report:

CrioestaminalRMS RegrowLifeCellBoyalifeVcanbioKrioEsperiteBeikebiotechCryo-cellPacifiCordCryo StemcellCells4lifePBKM FamiCordStemade BiotechCellsafe Biotech GroupAmericordViaCordCordlife GroupCCBCFamilycordCBRStemCyte

The research report also studied the key players operating in the global Stem Cell Banking Market. It has evaluated and elucidated the research and development statuses of these companies, their financial outlooks, and their expansion plans for the prediction period. This research report also includes the list of planned initiatives that clearly explain the achievements of the Stem Cell Banking companies in the recent past.

Global Stem Cell Banking Market Regions Analysis:

Regional analysis is a highly all-inclusive part of this report. The geographical analysis of the global Stem Cell Banking Market has been showed in four major regions, namely the Asia Pacific, North America, Europe, and the rest of the world containing Latin America and the Middle East and Africa.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.globalmarketers.biz/discount_inquiry/discount/135432

The competitive landscape of the Stem Cell Banking market is described in terms of the players and their statistics. The research on the Stem Cell Banking will be applicable to investors, business owners, industry experts, and various c level peoples. The report also creates a clear picture of the various factors that will drive the Stem Cell Banking Market in the years to come. This report offers a SWOT analysis of the global market.

The Type Coverage in the Market are:

Placental Stem Cells (PSCs)Human Embryo-derived Stem Cells (HESCs)Bone Marrow-derived Stem Cells (BMSCs)Adipose Tissue-derived Stem Cells (ADSCs)Dental Pulp-derived Stem Cells (DPSCs)Other Stem Cell Sources

The Application Coverage in the Market are:

Personalized Banking ApplicationsClinical ApplicationsHematopoietic DisordersAutoimmune DisordersOther DiseasesResearch ApplicationsDisease Treatment StudiesLife Science ResearchDrug Discovery

The Stem Cell Banking market analysts and researchers have done wide analysis of the global Stem Cell Banking industry with the help of research methodologies such as PESTLE and Porters Five Forces analysis. They have provided exact market data and worthwhile recommendations with an aim to help the key players to gain an insight into the overall current and future market scenario.

The study analyses the following key business aspects:

Table ofContents

Global Stem Cell Banking Market Research Report 2020-2026

Chapter 1 Stem Cell Banking Market Overview

Chapter 2 Global Economic Impact on Stem Cell Banking Industry

Chapter 3 Global Market Competition by Key Vendors

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Production, Revenue (Value), Price Trend by Type

Chapter 6 Global Stem Cell Banking Market Analysis by Application

Chapter 7 Manufacturing Cost Analysis of Stem Cell Banking Market

Chapter 8 Marketing Strategy Analysis, Traders

Chapter 9 Stem Cell Banking Market Factors Analysis

Chapter 10 Global Stem Cell Banking Market Forecast up to 2026

Get Full Report With Complete TOC @ https://www.globalmarketers.biz/report/life-sciences/global-stem-cell-banking-market-report-2019,-competitive-landscape,-trends-and-opportunities/135432#table_of_contents

Go here to see the original:
Global Stem Cell Banking Market with Covid-19 Effect Analysis, Growth, Research Findings, Type, Application, Element Global Trends and Forecast to...

The Plasma Therapy market research report added by Market Study Report, LLC, is an in-depth analysis of the latest trends persuading the business outlook. The report also offers a concise summary of statistics, market valuation, and profit forecast, along with elucidating paradigms of the evolving competitive environment and business strategies enforced by the behemoths of this industry.

The Plasma Therapy market report provides with a broad perspective of this business space and contains crucial insights such as current and predicted remuneration of the industry, in consort with its size and valuation over the estimated timeframe.

Request a sample Report of Plasma Therapy Market at:https://www.marketstudyreport.com/request-a-sample/2448306?utm_source=scientect.com&utm_medium=AG

The study assesses the key factors that are positively affecting the industry landscape based on revenue generated as well as market growth. Additionally, the document analyzes the current trends that define this market while evaluating the challenges & limitations as well as the growth factors of this domain.

Key aspects of Plasma Therapy market report:

Regional analysis of Plasma Therapy market:

Plasma Therapy Market Segmentation:

Product types and application scope of Plasma Therapy market:

Product landscape:

Product types:

Key factors highlighted in the report:

Application Landscape:

Application segmentation:

Details specified in the document:

Additional information enlisted in the document:

Ask for Discount on Plasma Therapy Market Report at:https://www.marketstudyreport.com/check-for-discount/2448306?utm_source=scientect.com&utm_medium=AG

Competitive arena of the Plasma Therapy market:

Key players in the Plasma Therapy market:

Major aspects enlisted in the report:

Report Objectives:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-plasma-therapy-market-growth-status-and-outlook-2020-2025

Some of the Major Highlights of TOC covers:

Plasma Therapy Regional Market Analysis

Plasma Therapy Segment Market Analysis (by Type)

Plasma Therapy Segment Market Analysis (by Application)

Plasma Therapy Major Manufacturers Analysis

Related Reports:

1. Global Induced Pluripotent Stem Cells (iPSCs) Market Growth (Status and Outlook) 2020-2025This report categorizes the Induced Pluripotent Stem Cells (iPSCs) market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-induced-pluripotent-stem-cells-ipscs-market-growth-status-and-outlook-2020-2025

2. Global Ergothioneine (EGT) Market Growth (Status and Outlook) 2020-2025Ergothioneine (EGT) Market report covers the market landscape and its growth prospects over the coming years, the Report also brief deals with the product life cycle, comparing it to the relevant products from across industries that had already been commercialized details the potential for various applications, discussing about recent product innovations and gives an overview on potential regional market.Read More: https://www.marketstudyreport.com/reports/global-ergothioneine-egt-market-growth-status-and-outlook-2020-2025

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

See the original post:
Plasma Therapy Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2025 - StartupNG

By Clare Wilson

NIH/National Institute of Allergy and Infectious Diseases

Throughout the coronavirus pandemic there have been fierce debates over the science when to lock down, whether face coverings help and whether children are less susceptible, for example. The latest row is over whether we have been ignoring a crucial part of our immune response to the virus: T-cells.

This matters because if people have more immunity to the virus than we thought, then perhaps wecould abandon some covid-19 countermeasures. This was the case made by US President DonaldTrumps newest adviser oncovid-19, Scott Atlas at Stanford University in California. It has also been championed by others who argue against lockdowns. Is there any truth to the idea?

The immune system has two main arms to fight off pathogens such as the coronavirus. The one we hear most about consists of antibodies, small molecules that can recognise specific pathogens and target them for destruction.

Advertisement

Antibodies against the coronavirus can be measured in the blood and so surveys quickly began to gauge the proportion of people who have them. But even in places hit hard by the pandemic, antibody levels arent high enough to give herd immunity, which occurs when enough people are immune to the virus that it can nolonger easily spread.

Researchers have estimated that 65 per cent of a population would need to be immune to achieve herd immunity, based on how contagious the virus is. In London, antibody levels were about 10 per cent between 26 April to 9 August. For England as a whole, as with many European countries, it is insingle digits.

These levels are widely taken as indicating how many people have been infected by the coronavirus. But the picture is more complex than this because of the second arm of our immune system, T-cells. Antibodies are sometimes seen as more important because they can stop viruses from entering the body. But once viruses make it inside, only T-cells can kill infected cells.

It takes a few days to obtain results for tests of T-cell activity against the coronavirus, compared with as little as 90 minutes for antibody tests, but a few groups have been testing on a small scale. They have found T-cells that react to the coronavirus in 10 to 50 per cent of people tested.

That doesnt necessarily mean that up to half the population isimmune to covid-19, says Alessandro Sette at the La Jolla Institute for Immunology in California. Some of these studies, including one by Sette and his colleagues, looked at blood donations given before the current pandemic, to test for pre-existing immunity to the coronavirus. Others examined samples from people with covid-19.

The most likely explanation isthat the pre-pandemic blood samples that tested positive were from people who had previously caught milder coronaviruses, such as the ones that cause colds, and their T-cells are reacting to the one that causes covid-19. It is probable, although by no means definite, that such people would get less sick with covid-19, but they could still get infected and pass it on to others, says Sette.

However, a Swedish study that tested about 200 people, including some known to have had covid-19 and their family members, found that those who had been sickest with covid-19 had more T-cell activity. This suggested it was directed against the current coronavirus, not old ones, says Marcus Buggert at the Karolinska Institute in Stockholm, who worked on the study. But we cant say every single T-cell was induced by this new virus, he says.

As with antibodies, it is unclear how long T-cell immunity will last. I have seen [people] using our data to say we should open up society. I definitely do not want that, says Buggert.

T-cells could explain some puzzling anomalies in antibody testing. We have had people with confirmed cases of covid-19. Their antibody tests have come back negative, but their T-cells tested positive. That suggests antibody tests are not telling us the whole picture, says James Hindley at UKfirm Indoor Biotechnologies, which has developed a relatively fast and simple T-cell test.

The firms work hasnt yet beenpublished, and its test has sofar only been used on about 100people. But Hindleys team has found a few people testing positive for T-cell activity whose spouse had confirmed covid-19, yet they themselves somehow avoided it, as far as they know. It raises the question of whether the T-cells kept the virus at bay, says Hindley.

It is unlikely that questions such as these will be resolved until T-cell testing becomes much more common. Until then, says Hindley, the growing body of T-cell work should be seen as cause for hope but not complacency.

Sign up to our free Health Check newsletter for a round-up of all the health and fitness news you need to know, every Saturday

More on these topics:

Read the rest here:
What are T-cells and why have they become a political football? - New Scientist News

With the current corona virus pandemic in the United States and world wide, there are many scientists working very diligently to come up with an effective vaccine to reduce the significant healthcare impact of this virus. They are also evaluating and working on the various treatments options for the many people who have been infected with this virus. Therefore, I believe it is timely at this time to again review the importance of our human immune system and vaccines that can provide herd immunity.

Human Immune System The overall function of our human immune system is to prevent or limit infection. The primary job of our immune system is to distinguish between our normal, healthy cells and possible other dangerous cells, such as viruses and bacteria that may come into our blood stream. Our immune system is always on duty to look for and recognize these possible infectious viruses and bacteria. The immune system looks closely at these potentially infectious cells to do all it can to prevent us from getting an infection.

Know that we rely on our immune system every day to help us fight off infections and keep us healthy. Our immune system contains numerous cell types that either circulate throughout the body or reside in our particular body tissues. Each cell type plays a unique role, with different ways of performing their function to fight off infections. Further, many world wide medical and scientific researchers are working diligently at this time to develop a vaccine to effectively prevent the corona virus.

Vaccines When we receive a vaccine in our body, our powerful human immune system notes that this is a foreign potentially dangerous substance and promptly begins to make antibodies to fight it off. Here is the true positive impact of vaccines on USA health today. Our federal government reports that because of USA children receiving the recommended childhood immunizations, around 20 million illnesses and more than 40,000 deaths are prevented, resulting in approximately $70 billion in health care savings. Vaccinations are effective primarily due to two factors. First, once a person is immunized against a specific disease producing organism, the rate of that disease, as well as its associated asymptomatic carrier state, is decreased. Second, when a large population is immunized, unvaccinated individuals may also benefit from a reduced risk of exposure to these disease producing organisms.

Herd Immunity Herd immunity is a form of indirect protection from infectious disease that occurs when a sufficient percentage of a population has become immune to an infection, whether from vaccination or from previous infections, thereby reducing the likelihood of infection for individuals who lack immunity. Following is a brief review of the two ways we can receive herd immunity.

So, how do we achieve herd immunity? There are two ways this can happen. 1. We can develop resistance naturally. When our body is exposed to a virus or bacteria, it makes antibodies to fight off the infection. When we recover, our body keeps these antibodies, and then our body will defend against another infection of this type. 2. Vaccines will also build herd immunity. They make your body think a virus or a bacteria has infected it. You dont get sick, but your immune system still makes protective antibodies. The next time your body meets that bacteria or virus, it is ready to fight it off. Perhaps the greatest example the effectiveness of vaccines is the fact that the Salk vaccine essentially eliminated polio in the United States.

EDITORS NOTE: Dr. Jim Surrell is the author of The ABCs For Success In All We Do and the SOS (Stop Only Sugar) Diet books.Contact Dr. Surrell by email at sosdietdoc@gmail.com.

Today's breaking news and more in your inbox

Read more here:
Talk with the Doc: The human immune system and 'herd' immunity - Marquette Mining Journal

When you think about protein, you probablyworry about getting enough to repair muscle tissue after a tough workout, to help your body build lean, strong muscles and lose weight while boosting your natural calorie burn. All that's true but protein also serves another critical function in the body: It helps power your immune system, stoking the cells that you need to fight off infection, both bacterial and viral, and keep your guard up against illness of all kinds.

Protein plays an important role in powering your body'sT-cells, the agentsthat go out and attack opportunistic invaders that can get into your bloodstream and cause infection, and if you lack adequate protein intake, it can impair immune reaction, studies have found. Adiet low in protein leavesyou open to fatigue, weakness, and low immune response, all the more reason you need to get your essential amino acids from the food you eat (which is better than supplements). Meanwhile, your body is just as happy to get its full complement of protein from plants.

Proteins make up the framework of your cells, including the cells of the immune system and just about every other. But you don't have to worry if you're eating mostly plant-based foods, since the source of protein is less important than getting a full array of essential amino acids, specifically the 9 ones your body can't make enough of on its own.

In rare cases of protein deficiency (very seldom in a healthy US population other than those patients being treated with chemo), your immune system can stall, but the more frequent scenario of eating too much protein can also dampen downyour immune system by overtaxing your kidneys, which can't flush it fast enough. Americans, while obsessed with eating enough protein, are likely to eattoo much, according to experts. On average weeat up to twice as much protein as they need, about 100 grams a day when 60 is closer to the average that most people should get. The latest studies show thatthe right amount of protein is critical for your immune system to be healthiest.

In hospitals where patients lack appetite and treatments can zap their immunity, especially when someone is on chemotherapy for cancer, they are often given arginine, an amino acid that contains the most nitrogen of any, and has been shown to help boost immunity and speed up healing, according to the latest research.Another amino acid, glutamine, travels in your blood cells to offer your intestinal cells curative effects, which can prevent microbial contamination from the food you eat. But for most of us, supplements are not the answer, a healthy diet with a variety of vegetables, grains, legumes, fruits, nuts, and seeds will do it.

"Most healthy adults should aim to get around .8 to 1.2 grams of protein per kilogram of body weight per day, or roughly 55 to 80 grams of protein for a 150 lb adult," saysKatie Mikus, Manager of Scientific Affairs for Glanbia,which makes a plant-basedsupplementcalled Gold Standard 100% Plant with 24 grams of protein and4 Grams of Naturally Occurring Glutamine. For the right amount of protein for your size, activity level, age, and gender, check out this handy calculator here."Those looking to build or maintain muscle mass may wish to consume as much as 2.2 grams of protein per kilogram body weight per day," she adds.

When it comes to protein quality, look for protein sources that are easily digested and contain all 9 essential amino acids. Essential amino acids are those that must be consumed through whole foods or supplements because the body cannot make sufficient quantities to meet demand.

The richest plant sources of proteins tend to be legumes like soybeans, chickpeas, and beans and whole grains like quinoa and amaranth as well as certain vegetables, nuts, seeds and fruit. For a complete list of the best sources of plant-based proteins, see the 20 top vegetables for protein, compiled by The Beet.

Many plant-based proteins are "incomplete,"meaning they lack one or more of the 9 essential amino acids your body can't make on its own. "Complimentary incomplete plant proteins can be combined to create a complete protein. For example, grains tend to be low in lysine and high in methionine and cysteine, whereas legumes tend to be high in lysine and low in methionine and cysteine," Mikus explains. "So combining rice and beans will give you a complete protein, or peanut butter and whole wheat bread are examples of complementary proteins that make a complete protein when eaten together."

Complimentary plant proteins dont necessarily have to be eaten together as long as you consume protein from a variety of plant sources throughout the day. For more on how to get your complete proteins, see The Beet's story on perfect plant-based proteins.

But rather than worry about getting all 9 essential amino acids at one sitting, simply eat a varied plant-based diet throughout the day and your body can take care of the rest. One easy way is to combinerice and beans,but you can also just make sure to get a variety ofplant-based foodsand be sure to include legumes like chickpeas in your lunch salad. You don't have to eat all the building blocks at once, as nutritionists once thought since your body has the extraordinary ability to assemble them into the necessary proteins to operate at peak performance.

Eating to support a healthy immune system is as simple as following the basic principles of healthy eating. Your best bet: Consume a variety of foods and try to fill half your plate with fruits and vegetables, and make at least half of the grains you eat whole grains. Try to limit processed foods, excess sodium, added sugars, and saturated fats which drive up inflammation. In addition to proper nutrition and hydration, getting adequate sleep, minimizing and managing stress, and incorporating regular physical activity are all healthy lifestyle choices that help support a healthy immune system.

Go here to see the original:
Eat Protein to Boost Your Immune System. Here's How Much You Need - The Beet

Scientists have used artificial intelligence to reveal an aggressive form of pancreatic cancer that is more likely to respond to immunotherapy, in the most extensive analysis of the immune landscape of these tumours to date.

Pancreatic neuroendocrine cancer starts in cells that produce hormones such as insulin. Once it spreads, only one in four people will survive for more than five years, and new treatment options are desperately needed.

The new study found that a particularly aggressive type of these tumours can evade immune attack by hijacking the immune systems response to viral infections, and reveals possible targets for immunotherapy for this rare, hard-to-treat form of pancreatic cancer.

Next, the researchers plan to translate their findings into new clinical trials to test the possible benefit of immunotherapies in those patients most likely to respond.

Scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, working with colleagues at the University and Hospital Trust of Verona, Italy, used AI and genetic analysis to study 207 tumour samples from patients with pancreatic neuroendocrine tumours for the levels of 600 immune-related genes.

Comparing four separate forms of the disease, they found that samples of the most aggressive form, known as metastases-like primary tumours, saw changes in activity of 74 immune-related genes, compared with changes in only 12 immune system genes in the more benign insulinoma-like tumours.

The study was published in the journal Gut today (Tuesday), and was funded by the NIHR Biomedical Research Centre at The Royal Marsden and The Institute of Cancer Research (ICR), the ICR itself, and by Italian charities including the AIRC Foundation for Cancer Research.

The scientists found that 83 per cent of aggressive, metastatic-like tumours contained particularly high levels of a gene called TLR3, part of a damage-alert system that mimics the infection response triggered by viruses, drawing immune cells to the tumour.

This damage response is related to a form of programmed cell death that occurs when theres not enough oxygen which can happen inside metastatic-like tumours, which tend to be larger in size.

The researchers believe that by hijacking the damage response through TLR3 which helps flag tumour cells to the immune system cancer cells can escape from the immune system, leading to the tumours ability to grow and evolve.

The ICR, a charity and research institute, is raising the final 2 million for its revolutionary new Centre for Cancer Drug Discovery, dedicated to overcoming cancers ability to evolve resistance to treatment.

Importantly, the ICR team also studied the presence of known targets for existing immunotherapies in all four kinds of pancreatic neuroendocrine tumours.

They found that the most aggressive type had the highest levels of an immune marker known as PD-L1, which suggests they can be targeted with immunotherapies designed to take the brakes off the immune system so it can attack tumour cells, known as checkpoint inhibitors.

Immunotherapy treatments have been shown to work very well in some tumour types but they dont work for everyone and have only shown modest benefits in this form of pancreatic cancer, so it is important to be able to identify the patients who are most likely to benefit from immunotherapy.

The researchers now hope their results will lead to clinical trials to test the benefit of immunotherapies, either alone or in combination with other treatments, for patients with the metastatic-like form of pancreatic neuroendocrine tumours.

Dr Anguraj Sadanandam, Team Leader in Systems and Precision Cancer Medicine at The Institute of Cancer Research, London, said:

Our new study offers an important basis from which to start developing new treatment strategies for a rare form of cancer, which starts in the hormone-producing cells of the pancreas.

We found that there is a complex interplay between cancer and immune cells in the most aggressive type of pancreatic neuroendocrine tumours, which suggests immunotherapy could work for patients with this form of the disease.

Our findings could help to pick out those patients most likely to benefit from immunotherapy and were keen to translate our work into clinical trials to test the benefit of different immunotherapeutic strategies to tackle this hard-to-treat form of pancreatic cancer.

Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:

Pancreatic cancers have some of the poorest survival rates so its hugely encouraging to see such an extensive study of the immune landscape of a rare form of pancreatic cancer, looking at the underlying biology to inform the best way forward in treating the disease.

Its fascinating to see a mechanism unveiled by which these tumours develop the activity of a highly distinct set of immune-related genes, as this could not only underlie the immune escape of these tumours, but also feed into their ability to evolve one of the biggest challenges in cancer research and treatment today.

Immunotherapy has transformed the outlook for a range of different cancer types, and I look forward to seeing these new findings progress to clinical trials, which might lead to a more personalised way of treating people with pancreatic neuroendocrine tumours.

Read the original:
Hard-to-treat pancreatic cancer hijacks immune system and could be targeted with immunotherapies - PharmiWeb.com

Magnetude Jewelry Fall 2020

MT AIRY, Md. (PRWEB) September 01, 2020

In a fall like no other, Magnetude Jewelry finds itself with the right product at the right time. Interchangeable fashion jewelry pendants and necklaces that allow one to change the stone based on mood and occasion is already a hot fashion trend, but in a year where everybody is looking for strategies to boost and improve the immune system, Magnetudes second key ingredient is about what the products are made of: Neodymium magnets.

Most people dont realize that their electrical energy is diminished by EMFs and can decrease their immunity, explains Magnetude co-founder Dr. Tracey Diner, DC. Wearing Magnetude Jewelry along with other healthy regiments like vitamins, good diet, and exercise, help us build up a stronger resistance to viruses and germs.

EMFs come from many sources in this high-tech age, including cell phones, Wifi, cell towers, and other electronic activity. Dr. Diner, a wellness doctor, and her partner Candice Loren, a noted artist and jewelry designer, started this company to pursue their joint passions for unique design and better health.

Magnetude Jewelry incorporates the most powerful healthy Neodymium magnets, energy elements of infrared, negative ion, and germanium in all of their interchangeable necklaces, bracelets, and earrings. These energy frequencies help to replenish the cellular function that EMFs destroy. With the fall flu season about to start and the expected second wave of COVID-19 on the horizon, innovative ways to stay healthier are at a premium.

Magnetude Jewelry should be worn all the time, so it has been designed with thousands of combinations to match any clothing the wearer chooses. There are product lines for men and pets, and this month Dr. Diner says she is launching a childrens line because children are at higher risk from EMFs, absorbing up to 10 times that of adults.

For further information about Magnetude Jewelry and the science behind it, visit http://www.MagnetudeJewelry.com.

Share article on social media or email:

Excerpt from:
FALL 2020 - Magnetude Jewelry Fashion Line Supports the Immune System - PR Web

Wells: Is there any downside of giving people plasma, even if you dont know if its going to be specifically helpful to them?

Hamblin: There theoretically shouldnt be, but there could, and that is the reason that you dont just authorize these things, that you have an FDA to make sure that something is safe and effective ...

Kola: It seems like people have antibodies within three months of them having COVID-19. And I definitely had antibodies back in May when I was given an antibody test, but then, given the news out of Hong Kong, it looks like those antibodies might wane over time? When I imagine the plasma, am I imagining blood that has actual antibodies in it, or does it have the memory of how to make antibodies? Whats actually in the plasma?

Hamblin: Thats a great question Youre just getting the antibodies themselves. The act of producing them will involve the white blood cells that should be taken out of plasma

Wells: Theyre the things that make the antibodies ... and that do have the memory of how to make them?

Hamblin: Right When you transmit plasma, youre not teaching someone to make antibodies. Thats what happens by exposing them to the virus. Thats vaccination. Its called passive immunization, where you temporarily have these antibodies until your blood clears them out. Theyre gone, and youd theoretically have to get another transfusion.

Kola: So there would be the possibility that, having had COVID-19 in March, and maybe being called upon to donate plasma in October, my blood might not have the antibodies anymore that it had in May.

Hamblin: Yeah, that remains possible.

Kola: Wow.

Wells: Is that upsetting?

Kola: I think its like much to do with COVID: Just one of the sort of confusing complexities of it is that I know that I had the antibodies at one point. I cant know for sure that I have them now without another antibody test. And being someone who had it relatively early, my experience of the virus is myself and everyone around me learning about it almost in real time ...

Hamblin: Well, if it helps reassureI guess Katherine can explain the immunology here, because we had a whole episode on thisbut there is more to your bodys memory than just the presence of antibodies themselves. There are immune-messaging pathways such that even if you lost your antibodies, its possible that your body might be able to kind of quickly make new ones and call them back and have other ways of fighting off this virus so that, if you are reinfected, it is not so bad, even if you dont actively have the antibodies.

Kola: Can you explain how people like me who had COVID-19 and are hopeful about immunity should interpret the information from Hong Kong, because that was obviously, on the face of it, quite scary for people whove had an experience of COVID that they wouldnt wish to go through again.

Here is the original post:
Listen: Plasma and Immunity - The Atlantic